2023
Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study
Milgrom S, Kim J, Pei Q, Lee I, Hoppe B, Wu Y, Hodgson D, Kessel S, McCarten K, Roberts K, Lo A, Cole P, Kelly K, Cho S. Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study. British Journal Of Haematology 2023, 201: 1192-1199. PMID: 36922022, PMCID: PMC10247420, DOI: 10.1111/bjh.18734.Peer-Reviewed Original ResearchConceptsRapid early respondersEvent-free survivalTotal lesion glycolysisBaseline total lesion glycolysisIntensive therapyRisk stratificationTumor burdenHodgkin's lymphomaEarly respondersMTV/TLGFour-year event-free survivalBaseline metabolic tumor burdenExcellent event-free survivalHigh-risk Hodgkin lymphomaChildren's Oncology Group studyPoor event-free survivalMaximum standardized uptake valueResponse-adapted approachBaseline PET scanMetabolic tumor burdenStandardized uptake valueIntensified therapyLesion glycolysisBaseline PETTumor SUV
2021
PET-Based Quantification of Baseline Metabolic Tumor Burden Improves Risk Stratification in High-Risk Hodgkin Lymphoma: A Children's Oncology Group Study
Milgrom S, Kim J, Hoppe B, Pei Q, Wu Y, Lo A, Kessel S, McCarten K, Roberts K, Hodgson D, Schwartz C, Friedman D, Kelly K, Cho S. PET-Based Quantification of Baseline Metabolic Tumor Burden Improves Risk Stratification in High-Risk Hodgkin Lymphoma: A Children's Oncology Group Study. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: s79-s80. DOI: 10.1016/j.ijrobp.2021.07.192.Peer-Reviewed Original ResearchRapid early respondersSlow early respondersMetabolic tumor volumeTotal lesion glycolysisBaseline metabolic tumor burdenHigh-risk Hodgkin lymphomaBaseline tumor burdenMetabolic tumor burdenTumor burdenIntensive therapyHodgkin's lymphomaPET scansEarly respondersCutoff valueEvent-free survival rateChildren's Oncology Group studyPositron emission tomography scanMaximum standardized uptake valueCycles of chemotherapyInitial disease burdenNodular sclerosis histologyResponse-adapted approachBaseline PET scanKaplan-Meier analysisAge 15.5 years